-
Basel, May 4, 2022 — Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with fulvestrant in the first-line subgroup of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer. The analysis of…Reimagine MedicineOncologyMedical InnovationsCancer
-
Ad-hoc-Mitteilung gemäss Art. 53 KRReimagine MedicineMedical InnovationsInnovationAd Hoc
-
Annonce événementielle selon l’art. 53 RCReimagine MedicineMedical InnovationsInnovationAd Hoc
-
Ad hoc announcement pursuant to Art. 53 LRReimagine MedicineMedical InnovationsInnovationAd Hoc
-
Basel, April 11, 2022 — Novartis today announced promising clinical data for JDQ443, an investigational selective, covalent, and orally bioavailable KRASG12C inhibitor at the annual meeting of American Association for Cancer Research (AACR). Comprehensive information on the discovery of JDQ443 is also included in a poster being presented on…Reimagine MedicineOncologyMedical InnovationsCancer
-
Thierry Diagana and his team are on a quest to discover new therapeutics for malaria. He believes malaria elimination is within our grasp, but emerging drug resistance could jeopardize the hard-fought progress.
Access to HealthcareInfectious DiseasesMalariaMedical InnovationsTropical Diseases -
Basel, April 6, 2022 — Novartis today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Vijoice® (alpelisib) for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.1 Vijoice is the first…Reimagine MedicineRare DiseasesOncologyMedical Innovations
-
Ad hoc announcement pursuant to Art. 53 LR Reimagine MedicineOncologyMedical InnovationsCancerAd Hoc
-
Ad-hoc-Mitteilung gemäss Art. 53 KRReimagine MedicineMedical InnovationsInnovationAd Hoc
-
Annonce événementielle selon l’art. 53 RCReimagine MedicineMedical InnovationsInnovationAd Hoc
-
Ad hoc announcement pursuant to Art. 53 LRReimagine MedicineMedical InnovationsInnovationAd Hoc
-
Basel, 4. März 2022 – Die Aktionärinnen und Aktionäre von Novartis stimmten heute an der ordentlichen Generalversammlung (GV) des Unternehmens allen Vorschlägen des Verwaltungsrats zu. In Übereinstimmung mit der Schweizer COVID-19-Verordnung 3 wurde die Generalversammlung 2022 ohne physische Anwesenheit der Aktionäre durchgeführt. Dementsprechend…Reimagine MedicineMedical InnovationsFuture of Healthcare
-
Thierry Diagana and his team are on a quest to discover new therapeutics for malaria. He believes malaria elimination is within our grasp, but emerging drug resistance could jeopardize the hard-fought progress.